Literature DB >> 18766406

Cytology from pancreatic cysts has marginal utility in surgical decision-making.

Ajay V Maker1, Linda S Lee, Chandrajit P Raut, Thomas E Clancy, Richard S Swanson.   

Abstract

BACKGROUND: Preoperative diagnosis of pancreatic cystic neoplasms is problematic. We evaluated our experience with endoscopic ultrasound (EUS) to determine the utility of fine-needle aspiration cytology (FNAC) in surgical decision-making.
METHODS: Patients evaluated for pancreatic cysts with EUS fine-needle aspiration (FNA) from 3/1996-10/2003 were included. Patients undergoing both preoperative EUS-FNA and pancreatic resection were identified. FNAC read as a mucinous cystic neoplasm (MCN), suspicious for neoplasia, or mucinous epithelial/atypical cells were classified as "concerning." Cytology with no malignant cells was negative. FNAC read as indeterminate, atypical cells of undetermined significance, or possible contamination was nondiagnostic.
RESULTS: Of 95 patients evaluated with EUS FNAC, 29 underwent resection. On final pathology, 7/29 lesions (24%) were malignant [two neuroendocrine tumors, three adenocarcinomas, one invasive intraductal papillary mucinous neoplasm (IPMN), and one metastatic uterine tumor], 4/29 (14%) were benign (three serous cystadenomas and one chronic pancreatitis), and 18/29 (62%) were premalignant (ten MCNs and eight IPMNs). Seven patients had concerning FNAC. All seven harbored malignant or premalignant lesions. Nine patients had negative FNAC: three (33%) with benign lesions and six (67%) with premalignant lesions. Thirteen of the 29 patients (45%) had nondiagnostic FNAC with 12/13 (92%) harboring a malignant or premalignant lesion. Sensitivity, specificity, positive predictive value, and negative predictive value were 28%, 100%, 100%, and 18%, respectively.
CONCLUSION: The decision to proceed with nonoperative management should not be based on a negative or nondiagnostic FNAC alone, as 67% of negative and 92% of nondiagnostic specimens were associated with malignant or premalignant pathology.

Entities:  

Mesh:

Year:  2008        PMID: 18766406     DOI: 10.1245/s10434-008-0110-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  41 in total

Review 1.  Intraductal papillary mucinous neoplasia (IPMN) of the pancreas: its diagnosis, treatment, and prognosis.

Authors:  Robert Grützmann; Stefan Post; Hans Detlev Saeger; Marco Niedergethmann
Journal:  Dtsch Arztebl Int       Date:  2011-11-18       Impact factor: 5.594

Review 2.  Clinical approach to incidental pancreatic cysts.

Authors:  Austin L Chiang; Linda S Lee
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 3.  [Surgical therapy of intraductal papillary mucinous neoplasms of the pancreas].

Authors:  S Fritz; M W Büchler; J Werner
Journal:  Chirurg       Date:  2012-02       Impact factor: 0.955

Review 4.  Novel Biomarkers for Pancreatic Cysts.

Authors:  Harkirat Singh; Kevin McGrath; Aatur D Singhi
Journal:  Dig Dis Sci       Date:  2017-02-14       Impact factor: 3.199

5.  Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Authors:  Mohammad A Al Efishat; Marc A Attiyeh; Anne A Eaton; Mithat Gönen; Denise Prosser; Anna E Lokshin; Carlos Fernández-Del Castillo; Keith D Lillemoe; Cristina R Ferrone; Ilaria Pergolini; Mari Mino-Kenudson; Neda Rezaee; Marco Dal Molin; Matthew J Weiss; John L Cameron; Ralph H Hruban; Michael I D'Angelica; T Peter Kingham; Ronald P DeMatteo; William R Jarnagin; Christopher L Wolfgang; Peter J Allen
Journal:  Ann Surg       Date:  2018-08       Impact factor: 12.969

6.  Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia.

Authors:  Rachel E Simpson; Michele T Yip-Schneider; Katelyn F Flick; Huangbing Wu; Cameron L Colgate; C Max Schmidt
Journal:  Pancreas       Date:  2019-09       Impact factor: 3.327

Review 7.  Pancreatic Cysts in the Elderly.

Authors:  Luis F Lara; Anjuli Luthra; Darwin L Conwell; Somashekar G Krishna
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

Review 8.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

Review 9.  Management of mucin-producing cystic neoplasms of the pancreas.

Authors:  Stefan Fritz; Andrew L Warshaw; Sarah P Thayer
Journal:  Oncologist       Date:  2009-02-11

10.  Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasms.

Authors:  Dirk Bausch; Mari Mino-Kenudson; Carlos Fernández-Del Castillo; Andrew L Warshaw; Kimberly A Kelly; Sarah P Thayer
Journal:  J Gastrointest Surg       Date:  2009-09-17       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.